IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more
IO Biotech Inc (IOBT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -20.283x
Based on the latest financial reports, IO Biotech Inc (IOBT) has a cash flow conversion efficiency ratio of -20.283x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($911.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IO Biotech Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how IO Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IO Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IO Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Osia Hyper Retail Limited
NSE:OSIAHYPER
|
-0.012x |
|
Ekadharma International Tbk
JK:EKAD
|
0.029x |
|
Study King Co., Ltd.
TWO:6780
|
0.035x |
|
FACT II Acquisition Corp. Warrant
NASDAQ:FACTW
|
N/A |
|
Tamtron Group Oyj
HE:TAMTRON
|
0.105x |
|
K-Tech Solutions Company Limited Class A Ordinary Shares
NASDAQ:KMRK
|
N/A |
|
Hamelin Gold Ltd
AU:HMG
|
-0.017x |
|
CIC39 Corp
VN:C32
|
N/A |
Annual Cash Flow Conversion Efficiency for IO Biotech Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of IO Biotech Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.02 Million | $-82.35 Million | -1.752x | -225.12% |
| 2023-12-31 | $133.16 Million | $-71.74 Million | -0.539x | -25.24% |
| 2022-12-31 | $138.85 Million | $-59.73 Million | -0.430x | -124.28% |
| 2021-12-31 | $211.92 Million | $-40.65 Million | -0.192x | +94.99% |
| 2020-12-31 | $2.60 Million | $-9.96 Million | -3.825x | -163.28% |
| 2019-12-31 | $-1.47 Million | $-8.89 Million | 6.044x | -- |